Chidubem Chukwuma’s Post

I am delighted to present the findings of my research, which focuses on the pharmacokinetic profiling of coumarins found in Aegle marmelos (Bael Fruit). These bioactive compounds are highly valued for their effectiveness and are abundant in this exceptional fruit, offering promising avenues for pharmaceutical exploration. Our study delved into understanding the pharmacokinetics of coumarins utilizing advanced computational tools such as SwissADME. Our discoveries encompass insights into their solubility in water, ability to penetrate the blood-brain barrier (BBB), and potential therapeutic uses. This research significantly contributes to advancing drug development and personalized medicine.Let's uncover the pharmacological potential of natural compounds and their impact on tailored drug therapies. #research #drugdevelopment #Pharmacokinetics #coumarins #herbal

Getting to First in Human clinical studies can be a major challenge if the studies conducted to support the intended study plan are not appropriate. Hear from the industry experts (great panel of speakers) on how to do it right and get to clinic expeditiously. Remember to learn what is "phase appropriate" for Phase 1.

#NEW #FDAGrant Simulations Plus, Inc., University of Bath, Colorado School of Mines, University of Reading Maxime Le Merdy, Jessica Spires, Jasmina Novakovic 🎯 The focus? Expanding and validating a state-of-the-art PBBM #PBPKmodeling solution on the robust #GastroPlus platform. Spearheaded by the dynamic Skin Biosciences group and university partners this initiative generates groundbreaking in vitro data to amplify the #Transdermal Compartmental Absorption and Transit model. 👩💻 Why does it matter? The aim is to establish a potent alternative to in vivo studies for determining #bioequivalence in #topicalproducts. This could potentially transform regulatory decision-making, benefiting patients and the broader pharmaceutical industry. Read More 👇 https://lnkd.in/gmGg44NV #PharmaInnovation #FDA #SimulationsPlus #DrugDevelopment #CollaborationSuccess

🔍 Exciting News: Secured my 5th UK Design Patent! 🎉 Thrilled to announce the successful acquisition of my 5th UK design patent, marking a significant milestone in the field of pharmaceutical innovation. 🚀 This latest patent is particularly special as it represents the first design patent of the year! 🔬 Title: Equipment for the Preparation of Polymeric Micelles for Targeted Delivery in Alzheimer's Disease This cutting-edge equipment is a testament to our commitment to advancing targeted drug delivery in Alzheimer's disease. 🧠 The unique design facilitates the preparation of polymeric micelles, offering potential breakthroughs in therapeutic strategies for this challenging neurodegenerative disorder. Kudos to the dedicated team that has contributed to this achievement, showcasing our passion for pushing the boundaries of pharmaceutical research. 🌐 Looking forward to this innovation's positive impact on improving treatment options for Alzheimer's patients. #Innovation #Patent #Pharmaceuticals #AlzheimersResearch #DrugDelivery #PolymericMicelles #MedicalInnovation 🌟

🔬 Current Pharmaceutical Design 🔬 🚀 Impact Factor: 2.6 📚 Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed 📅 Volume 30, Issues 42, 2024 Current Pharmaceutical Design offers the latest research in rational drug design. Explore in-depth reviews and articles on medicinal chemistry, pharmacology, drug targets, and disease mechanisms. Each issue features expert guest editors on crucial therapeutic areas. 📝 Submit your research and be part of the new advancements in drug design. Stay at the forefront of pharmaceutical innovation! 🔗https://bit.ly/46LuRHA #PharmaceuticalResearch #DrugDesign #MedicinalChemistry #Pharmacology

PHARMACEUTICAL ADVANCEMENT THROUGH SYMBIOTIC FUSION: LEVERAGING CHEMOGENOMICS AND CHEMINFORMATICS IN PHARMACY 💊 💻 This refers to the integration of two key disciplines, chemogenomics and cheminformatics, to drive progress in the pharmaceutical industry. Chemogenomics involves studying the interaction between drugs and their target receptors on a genomic scale, allowing for a better understanding of drug efficacy and safety profiles. Meanwhile, cheminformatics utilizes computational methods to analyze chemical data, facilitating drug design, optimization, and prediction of pharmacological properties. By combining these approaches, researchers can expedite the drug discovery process, identify potential drug targets more accurately, and design molecules with enhanced therapeutic effects and reduced side effects. This symbiotic fusion holds promise for accelerating pharmaceutical development and improving patient outcomes. #drugdevelopment #pharmacy #cheminformatics #chemogenomics #drugdesign #computationalmodeling

CQDM. We celebrate. 15th anniversary of CQDM. Merck Canada contributes an additional $6 million to CQDM. Since CQDM's inception, Merck has been a valued and loyal partner, contributing more than $17.5 million over the 15 years of our partnership. Merck's commitment has made it possible to support more than 59 collaborative R&D projects, including a unique, globally competitive technology from Canadian biotech Mesentech. Mesentech is developing a platform to deliver highly potent drugs directly to the bone, thereby mitigating systemic drug side effects and increasing therapeutic efficacy, with important implications for the treatment of bone diseases such as osteoporosis, bone infections and bone cancers. Thanks to this technology, Mesentech has developed MES1022, which is now in clinical trials. Jennifer Chan, Executive Director of Policy and Government Affairs, Merck: ‘’Merck is proud to support CQDM in its mission to advance research and facilitate innovation in the healthcare field. As a founding member of CQDM, we are very pleased with the continued collaboration between the two organizations, seeking to consolidate research in academic/private partnership. The CQDM allows us to get closer to these entities to find innovative solutions for patients together.’’ See how CQDM has been ''Facilitating biopharma innovation'' since 2008 by consulting our website, including the section dedicated to our 15th anniversary: https://lnkd.in/gX-jtJig #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #anniversaire #anniversary

Daiichi Sankyo and Depixus have announced a strategic partnership to accelerate the development of RNA-targeted drug discovery. This collaboration will provide a dedicated approach to discovering new treatments for a range of diseases, while leveraging existing technologies and platforms specialised in the study of RNA 🧬😊 Daiichi Sankyo brings stabilising expertise and pharmaceutical criteria to the partnership, enabling Depixus to reach their common goals faster. This knowledge, combined with Depixus' comprehensive clinical data insights and entire drug discovery process, will create completely novel opportunities for the development of treatments 🧰🤝 This partnership is a unique step forward in accelerating RNA-targeted drug discovery. By leveraging existing markets and technologies and creating a dedicated approach, this collaboration is sure to make a big impact in the field of chemical biology 🔬🤩 #DS9411 #RNA #collaboration

In this collaboratively written op-ed article written together with Tracer CRO, read about recent trends in molecular imaging and drug development. Also, learn more about CD8 ImmunoPET™ imaging and Phase 0 clinical trials. Click here to read the article: https://buff.ly/3SolbNu Reach out to us to learn more about CD8 imaging in clinical trials at info@imaginab.com #Biotech #Immunooncology #Clinicaltrials #pharmaceuticals #drugdevelopment #molecularimaging #CD8

Exciting News from Cambridge Life Science! 🌟 Introducing the Cambridge Life Science Paracetamol Assay. Accurate, reliable, and efficient – our assay is designed to meet the highest standards in pharmaceutical and clinical research. Here’s why it stands out: ✅ High Sensitivity: Detects low levels of paracetamol with precision and offers widest reportable range on the market (no sample dilution required) ✅ Rapid Results: Provides fast turnaround times, saving you valuable research time. ✅ Easy Integration: Seamlessly fits into existing workflows with minimal setup. ✅ Robust and Reproducible: Ensures consistent results across multiple assays. Whether you are in clinical diagnostics, pharmaceutical, or toxicology, our paracetamol assay is a game-changer for your analytical needs. Join us in advancing clinical diagnostics with tools that push the boundaries of innovation and reliability. Learn more about the Cambridge Life Science Paracetamol Assay by contacting me at salma.elghadban@medsciencedistribution.com #clinicalsiagnostics #ParacetamolAssay #CambridgeLifeScience #ClinicalResearch #paracetamoloverdose #Innovation #nhs #pathology #biochemisty